糖脉康颗粒联合氯沙坦治疗2型糖尿病并发高血压的临床观察

目的：观察糖脉康颗粒联合氯沙坦治疗2型糖尿病并发高血压的临床疗效。方法：将120例2型糖尿病并发高血压患者随机平均分为观察组与对照组,观察两组治疗前后各项相关指标的变化及临床总体疗效。结果：治疗12周后,观察组的总有效率为91.7%,显著优于对照组的60.0%（P〈0.05）,观察组患者的空腹和餐后血糖、糖化血红蛋白与治疗前的差值分别为（1.02±0.99）mmol/L,（2.76±1.28）mmol/L,（0.62±0.23）%,收缩压与舒张压分别为（136.58±9.88）mmHg和（82.25±6.66）mmHg,对照组与之相应的值分别为（0.14±1.15）mmol/L,（0.52±1.19）mmol/L,（0.22±0.17）%,（152.20±7.75）mmHg和（92.85±5.68）mmHg,观察组改善程度均优于对照组（P〈0.05）。结论：糖脉康颗粒联合应用氯沙坦,对2型糖尿病并发高血压患者的空腹血糖、餐后血糖、糖化血红蛋白值的控制效果要优于单纯应用氯沙坦,治疗后患者的临床症状显著改善,总体疗效显著优于单纯应用氯沙坦。

Clinical Observation on Therapeutic Effects of Tangmaikang Granula with Losartan for Type 2 Diabetes with Hypertension

Objective： To investigate the therapeutic effects of Tangmaikang with Losartan on type 2 diabetes with hypertension. Methods： A total of 120 patients with type 2 diabetes with hypertension were randomly and evenly divided into observation group and control group. Then, the changes of associated indexes and total effective rates were compared between the two groups before and after treatment. Results： The total effective rate of observation group （91.7%） was significantly better than that of control group （60.0%）（P〈 0.05）. On the indexs ofFPG, 2hPG and HbAlc, the results of observation group （1.02± 0.99 mmol/L,2.76± 1.28mmol/L,0.62± 0.23%） were all better than those of control group （0.14 ± 1.15mmol/L, 0.52 ± 1.19mmol/L, 0.22 ± 0.17% ） （P〈0.05）. Conclusion： Tangmaikang with Losartan for type 2 diabetes with hypertension was better than Losartan only in the effectiveness on FBG, PBG and HbAlc. The symptoms of the patients were improved significantly, the total effective rate of observation group was significantly higher than that of control group.